Literature DB >> 8500719

Is small intestinal permeability really increased in relatives of patients with Crohn's disease?

G R May1, L R Sutherland, J B Meddings.   

Abstract

BACKGROUND: Patients with Crohn's disease have increased intestinal permeability, which may precede the development of clinical disease and be involved in disease pathogenesis. Subsequent studies have suggested that, as a group, first-degree relatives of patients with Crohn's disease do not have significantly increased small intestinal permeability rates. The present study proposes that conventional data analysis, used in these studies, may be inappropriate and has overlooked an important observation.
METHODS: Lactulose and mannitol permeabilities were defined in healthy controls and in patients with Crohn's disease and their first-degree relatives.
RESULTS: Intestinal permeability in relatives was similar to that in the control group, but a subpopulation had abnormally high permeability rates in the absence of clinical evidence for disease. Raw data from another investigator confirmed this finding in an additional study; consequently, it is concluded that the original hypothesis is still viable. A small proportion of individuals, at high risk of developing Crohn's disease, have increased intestinal permeability.
CONCLUSIONS: Increased intestinal permeability may precede clinical manifestations of Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500719     DOI: 10.1016/0016-5085(93)90638-s

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  87 in total

1.  Elevated basal intestinal mucosal cytokine levels in asymptomatic first-degree relatives of patients with Crohn's disease.

Authors:  Anant VK Indaram; Santa Nandi; Sam Weissman; Sing Lam; Beverly Bailey; Meyer Blumstein; Ronald Greenberg; Simmy Bank
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

Review 3.  Increased gut permeability in Crohn's disease: is TNF the link?

Authors:  P R Gibson
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

4.  The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action.

Authors:  Matthias Prager; Janine Büttner; Verena Haas; Daniel C Baumgart; Andreas Sturm; Martin Zeitz; Carsten Büning
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

5.  Bin1: a new player in IBD barrier dysfunction.

Authors:  Hyunji Ryu; Daniela Posca; Terrence Barrett
Journal:  Dig Dis Sci       Date:  2012-05-30       Impact factor: 3.199

Review 6.  Tight junctions on the move: molecular mechanisms for epithelial barrier regulation.

Authors:  Le Shen
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

Review 7.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

8.  The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration.

Authors:  Cristiano Rumio; Giuseppina F Dusio; Barbara Colombo; Anna Gasparri; Diego Cardani; Fabrizio Marcucci; Angelo Corti
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

9.  Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity.

Authors:  Christopher R Weber; David R Raleigh; Liping Su; Le Shen; Erika A Sullivan; Yingmin Wang; Jerrold R Turner
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 10.  Alterations in intestinal permeability.

Authors:  M C Arrieta; L Bistritz; J B Meddings
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.